MedPath

Infection Rate of Vertical Expandable Prosthetic Titanium Rib Implants (VEPTR)

Conditions
Infection
Registration Number
NCT01085669
Lead Sponsor
Centre Hospitalier Universitaire Vaudois
Brief Summary

The study is conducted to analyse the infection rate in children treated with VEPTR-Implants for severe spine or thoracic deformities.

Detailed Description

Spinal and thoracic deformities in children can be treated with vertical expandable prosthetic titanium ribs (VEPTR©, Synthes GmbH®) to stimulate thoracic and spinal growth. With these implants children's symptoms and conditions can be slowed, halted or even reversed. Because of the dynamic character of the deformity and the growth of the children, the implants have to be lengthened about every half a year. With each operation there is a small risk of infection, which might increase with number of previous surgeries. Implant associated infections are often not clinical apparent and only found in microbiological analysis. To objectify the infection rate, identify potential precursors of infections and the relevance of asymptomatic infections in children with these implants a prospective study is conducted.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
50
Inclusion Criteria
  • all patients admitted at the University Children's Hospital Basel in whom a VEPTR©-implant or parts of it will be removed.
Exclusion Criteria
  • obvious contamination of an explanted component occurred in the operating room.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Infection rate of VEPTR Implantstwo years
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Orthopaedic Department, University Children´s Hospital Basel

🇨🇭

Basel, Switzerland

Orthopaedic Department, University Children´s Hospital Basel
🇨🇭Basel, Switzerland
Daniel Studer, MD
Principal Investigator
Carol Claudius Hasler, MD, PhD
Contact
+41 685 5350
Carolclaudius.hasler@ukbb.ch

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.